Publications by authors named "M Kawana"
Background/aim: Sports mouthguard should be designed and fabricated adequately. The purpose was to propose a criterion for fabricating sports laminate mouthguard with adequate thickness for protect orofacial structures.
Materials And Methods: Ethylene vinyl acetate sheet (Sports Mouthguard) was fabricated using a pressure former.
Article Synopsis
- The study examined joint effusion in patients with temporomandibular disorders (TMDs) that involved disc displacement, using MRI images of 97 temporomandibular joints (TMJs).
- Of the TMJs evaluated, joint effusion was observed in 70 cases, primarily in the superior articular cavity, and the presence of myofascial or TMJ pain did not affect the occurrence of effusion.
- The findings indicated that joint effusion is more prevalent in cases of disc displacement without reduction and that the volume of synovial fluid in effusions was unaffected by the presence of pain.
Article Synopsis
- - Mavacamten is a groundbreaking drug approved for treating obstructive hypertrophic cardiomyopathy (oHCM), showing notable improvements in heart function and symptoms in 50 real-world patients.
- - Patients experienced significant reductions in heart wall thickness and related complications, with only a small number needing to temporarily stop treatment due to minor decreases in heart function.
- - The approach taken at the care center allowed for the rapid introduction and monitoring of this new therapy, reinforcing mavacamten's safety and effectiveness outside of traditional clinical trial settings.
BACKGROUND Heart failure is associated with structural brain abnormalities, including atrophy of multiple brain regions. Previous studies have reported brain atrophy in middle-aged patients with systolic heart failure. In this report, we present the case of a 21-year-old woman with idiopathic dilated cardiomyopathy, cardiac failure, and global cerebral atrophy due to reduced cerebral artery blood flow.
View Article and Find Full Text PDFArticle Synopsis
- Hypercontractility and arrhythmia are significant issues in hypertrophic cardiomyopathy (HCM), and while beta-blockers are the standard treatment, they can lead to unwanted side effects like fatigue and lowered cardiac output.
- Researchers screened 21 different beta-blockers and found that carvedilol, which is not commonly used for HCM, effectively reduces heart muscle contractility and arrhythmia through inhibition of the ryanodine receptor type 2 (RyR2) without dropping heart rate.
- The study suggests that carvedilol’s unique properties, particularly its R-enantiomer, may offer a promising alternative treatment for HCM patients, combining antiarrhythmic effects and reduced contractility without compromising overall heart performance.